Diaceutics PLC New AI and ML Capabilities Enhance DXRX Platform
June 07 2022 - 2:01AM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
07 June 2022
7 June 2022
Diaceutics PLC
("Diaceutics" or "the Company")
New AI and machine learning capabilities enhance DXRX
platform
Deepening data insights and further embedding DXRX within
customers' commercial processes
Diaceutics PLC, (AIM: DXRX), a leading diagnostic
commercialisation company which provides data, intelligence, and
analytics to the healthcare market has announced today significant
enhancements to its proprietary DXRX platform, improving the user
experience.
From within their DXRX dashboard, customers can now access three
new AI-powered tools, helping to ensure their medicines get to
patients quicker. They are Smart Trend Analysis, Next Best Step and
Event Alerts.
- Smart Trend Analysis: provides automated analysis of
key trends and changes within customer data to uncover
hidden insights including the production of bespoke, meaningful
commentary for use in reports, with the customer able
to customise the reports to focus on the datasets important
to them
- Next Best Step: provides automated identification as
to where in the ecosystem customers should target their
diagnostics investments in order to get patients tested
and treated faster
- Event Alerts: deliver just in time email notifications
on significant changes within the data, such as if a new
lab has started to offer diagnostic testing
These services are highly sought-after by Diaceutics customers
and previously relied on the expertise of the Diaceutics' data
analysis team or availability of the customers' own data science
resource. Now produced automatically, customer queries can be
answered more comprehensively and faster than ever before.
This increased functionality represents a significant step in
Diaceutics' strategy to embed its platform within its customers'
own digital systems and day-to-day commercial processes.
Scott Gamester, Vice President of Data and Platform
commented:
"This is an important new release for our customers, allowing a
greater level of self service and flexibility when using the DXRX
platform. Our smart trend analysis, next best step and event alert
capabilities also recognise that our customers are busy executives
and need these critical data insights as quickly as possible to
support clinical and sales teams internally and physician
prescribing externally.
All of this is made possible by our continued investment in
platform innovation and supports Diaceutics' long term goal of
seeing DXRX become an embedded part of the Pharma commercial
model."
Enquiries:
Diaceutics PLC
Nick Roberts, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
Diaceutics' data capability is one of the three key value
drivers it has integrated into its unique DXRX platform alongside
its global Lab network and product suite tailored for Precision
testing.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKABQFBKDOAK
(END) Dow Jones Newswires
June 07, 2022 02:01 ET (06:01 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024